Kymera Therapeutics

The innovative science behind Kymera’s approach Read More >

Inventing New Medicines

Pioneering Targeted Protein Degradation

News & Events

09/14/20

Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Read More
09/09/20

Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors

Read More

Targeted Protein Degradation

A New Way to Treat Disease

Kymera is a biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. Kymera is driven to invent transformative medicines for a wide variety of diseases where traditional drug modalities have failed to sufficiently unlock the appropriate biological solution.

A Powerful Drug Discovery Engine

Kymera has developed a proprietary targeted protein degradation platform called Pegasus which enables the design of highly selective small molecule protein degraders – heterobifunctional molecules with potent activity against disease-causing proteins. Thanks to its E3 Ligase Whole Body Atlas, Pegasus is expanding the universe of potential disease targets and possible treatments.

Promising New Therapies

We are rapidly advancing a broad and diverse pipeline of novel protein degraders. These are medicines designed to target high impact, previously undrugged or insufficiently drugged targets within validated biological pathways. Further, our strategic partnerships with other leading companies and organizations are allowing us to expand the reach of protein degrader medicines to treat more patients and diseases.